2.41
0.11 (4.78%)
| Previous Close | 2.30 |
| Open | 2.33 |
| Volume | 499,760 |
| Avg. Volume (3M) | 446,233 |
| Market Cap | 151,768,080 |
| Price / Sales | 44.93 |
| Price / Book | 5.38 |
| 52 Weeks Range |
| Profit Margin | -66.10% |
| Operating Margin (TTM) | -81.69% |
| Diluted EPS (TTM) | -0.310 |
| Total Debt/Equity (MRQ) | 1.13% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -32.98 M |
| Levered Free Cash Flow (TTM) | -5.98 M |
| Return on Assets (TTM) | -12.47% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Connect Biopharma Holdings Limi | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.67 |
|
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 40.65% |
| % Held by Institutions | 43.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Richmond Brothers, Inc. | 30 Jun 2026 | 535,612 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |